Australia's most trusted
source of pharma news
Posted 24 July 2024 AM
By the end of July a $397 million blockbuster will be off patent in Australia, and the first biosimilar is primed for launch.
Johnson & Johnson's monoclonal antibody Stelara is set to lose patent protection in Australia on 28 July, mirroring the loss of exclusivity in Europe where the pharma giant expects to greet biosimilar competition in the last week of the month. Although its US patents expired last year, as a result of settlements and agreements J&J does not expect competition in that country until the start of 2025.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.